Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Rish K Pai
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention
|
Keywords human cancers risk variants GWAS pQTL proteomics EHR therapeutic drug caffeine acetazolamide drug trial emulation Get full text access Log in, subscribe or purchase for full access. References 1. Nelson, M.R. ∙ Tipney, H. ∙ Painter, J.L. ... The support of human genetic evidence for approved drug indications Nat. Genet. 2015; 47:856-860 2. Diogo, D. ∙ Tian, C. ∙ Franklin, C.S. ... Phenome-wide association studies across large population cohorts support drug target validation Nat. Commun.
By Qing Li, Qingyuan Song, Zhishan Chen, Jungyoon Choi, Victor Moreno, Jie Ping, Wanqing Wen, Xiang Shu, Jun Yan, Xiao-Ou Shu, Qiuyin Cai, Jirong Long, Jeroen R. Huyghe, Rish K Pai, Stephen B. Gruber, Yaohua Yang, Graham Casey, Xusheng Wang, Adetunji T. Toriola, Bhuminder Singh, Ken S. Lau, Li Zhou Verified, Zichen Zhang, Chong Wu, Ulrike Peters, Wei Zheng, Quan Long, Zhijun Yin, Xingyi Guo
|
The American Journal of Human Genetics
Verified
Interobserver variability in the histologic evaluation of serrated epithelial change in inflammatory bowel disease among gastrointestinal pathologists: a comparison of two different definitions
Conflicts of interest None declared. References 1, , , . The development of serrated epithelial change in ulcerative colitis is not significantly associated with increased histologic inflammation. Am. J. Surg. Pathol. 2024; 48; 719–725. 2, , et al. Dysplasia detected in patients with serrated epithelial change is frequently associated with an invisible or flat endoscopic appearance, nonconventional dysplastic features, and advanced neoplasia. Am. J. Surg. Pathol. 2024; 48; 1326–1334. 3, , , , , .
Causal Debiasing for Unknown Bias in Histopathology - A Colon Cancer Use Case
The authors have declared no competing interest. The author(s) received no specific funding for this work. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Mayo Clinic institutional review board (IRB 806-96 and 18-11309).
Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials-a missing link. Authors' reply - Jairath - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
INVITED EDITORIAL Vipul Jairath Corresponding Author vipul.jairath@robartsinc.com orcid.org/0000-0001-8603-898X Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada Department of Epidemiology and Biostatistics, Western University, London, ON, Canada Alimentiv Inc.
An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials
ORIGINAL ARTICLE The complete affiliations for all authors are listed in Appendix 1. The Handling Editor for this article was Professor Jonathan Rhodes, and it was accepted for publication after full peer‐review. Summary Background Pouchitis is a condition with large unmet medical needs and no approved therapies. Lack of validated instruments to measure disease activity and treatment response is a major barrier to drug development.
Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy‐checkpoint inhibitory colitis. Authors' reply
INVITED EDITORIAL PDF ShareShare Abstract LINKED CONTENT This article is linked to Pai et al and Buckle & Christensen papers. To view these articles, visit https://doi.org/10.1111/apt.16142 and https://doi.org/10.1111/apt.16203 We thank Drs.
The significance of histological activity measurements in immune checkpoint inhibitor colitis
Summary Background Colitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy. Aims To investigate associations between clinical, endoscopic, and histological features with outcomes Methods We identified 149 patients from seven institutions with biopsy‐proven ICI colitis. Biopsies were evaluated for histological features including the Geboes score, and the Robarts histopathological index (RHI) was calculated.
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Summary Background The optimal ulcerative colitis biopsy protocol is unclear. Aim To evaluate the number of biopsies required to accurately assess microscopic disease activity in ulcerative colitis Methods Biopsies from patients with ≥4 rectosigmoid samples, and clinical and endoscopic data, were retrospectively obtained from a prospective biobank. Histology and endoscopic videos were read blindly.
Editorial: histologic normalisation in ulcerative colitis
Abstract LINKED CONTENT This article is linked to Cushing et al and Cushing and Ananthakrishnan papers. To view these articles, visit https://doi.org/10.1111/apt.15568 and https://doi.org/10.1111/apt.15621. Where the telescope ends the microscope begins, and who can say which has the wider vision? Victor Hugo, Les Miserables 1862 Histologic evaluation of disease activity is emerging as a key outcome measure for ulcerative colitis (UC) clinical trials for several reasons.
Editorial: evolving histological assessment of NASH. Authors' reply
INVITED EDITORIAL Rish K. Pai Corresponding Author E-mail address: rishkpai@gmail.com https://orcid.org/0000-0002-2692-221X Department of Laboratory Medicine & Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA Search for more papers by this author Brian G.
When to suspect and how to diagnose syndromic polyps and carcinomas of the gastrointestinal tract: focus on Lynch syndrome and colonic hamartomatous polyposis
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 Inflammatory/juvenile polyp characterized by expanded and edematous lamina propria with cystically dilated colonic crypts. Figure 2 A ganglioneuroma from a patient with PTEN-hamartoma tumor syndrome. Figure 3 Intramucosal lipoma from the same patient as in Figure 2 .
Definitions of response and remission for the Robarts Histopathology Index
Definitions of response and remission for the Robarts Histopathology Index Rish K Pai1, Reena Khanna2,3, Geert R D’Haens2,4, William J Sandborn2,5, Jenny Jeyarajah2, Brian G Feagan2, Niels Vande Casteele2,6, Vipul Jairath2,3,7 1 Department of Pathology and Laboratory Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA 2 Robarts Clinical Trials, London, Ontario, Canada 3 Department of Medicine, University of Western Ontario, London, Ontario, Canada 4 Academic Medical Center, University of...
Standardising the interpretation of liver biopsies in non‐alcoholic fatty liver disease clinical trials
Summary Background There is substantial variation in how histologic definitions and scoring systems of non‐alcoholic fatty liver disease (NAFLD) are operationalised. Aim To develop a consensus‐based framework for standardising histologic assessment of liver biopsies in clinical trials of NAFLD. Methods An expert panel of 14 liver pathologists and three hepatologists was assembled.
Definitions of response and remission for the Robarts Histopathology Index
The Robarts Histopathology Index (RHI) is a recently validated instrument that measures histological disease activity in ulcerative colitis.1 Given the increasing importance and use of histology in UC as a treatment outcome, additional evaluation and clarification of the definitions for histological remission and response using the RHI is needed. During the development of the RHI, we demonstrated that most patients in clinical or endoscopic remission had an RHI≤6.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Rish K
Contact Rish K, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack